hotspot -WSS

hotspot

author：Wikipedia 2025-09-30 06:21:54 - browse：68

Obesity conference attendees with a pink and blue Wegovy sign hanging from the ceiling above. -- obesity coverage from STAT — Wegovy, the obesity drug, was inescapable at the ObesityWeek conference in Dallas. Elaine Chen

DALLAS — Here at ObesityWeek, one of the largest conferences on obesity, Novo Nordisk and Eli Lilly are displaying more than a dozen studies that together carry the message: Our blockbuster weight loss treatments will be worth it for society.

But experts point out that much of this company-funded research does not include the cost of the drugs themselves, which sell at more than $10,000 per year in the U.S. and are meant to be taken indefinitely.

The two major pharmaceutical companies have seen interest skyrocket for their GLP-1-based drugs like Ozempic, Wegovy, and Mounjaro, a new generation of medications that can cut substantial amounts of weight. But insurance plans have been slow to grant wide access to obesity treatments, concerned that the vast amount of people eligible to take them, along with their high price, could lead to significant financial strain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Emergent cuts jobs, executive role in business shake

entertainment

WSS

BMI, flaws aside, is found to be useful estimate of body fat in youth

Cord blood banking comes at a high cost to babies

Anavex keeps shifting the goalposts in its clinical trials

BMI, flaws aside, is found to be useful estimate of body fat in youth

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

The Pandemic Treaty must support building strong health systems

Wikipedia

hotspot

focus

Novavax promises a turnaround & Lilly roils the obesity market

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

Medical leaders decry Supreme Court decision on affirmative action

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Wildfire smoke exposes gaps in outdoor worker protections

FDA's Pazdur wants cancer trials to range beyond China alone

Hepatitis C has a cure — but many Americans still lack access to it

What to know about Virgin Galactic's 1st mission taking paying customers to space

At least 13 dead in Texas as scorching temps continue

In same hospitals, Black patients receive fewer opioids than white patients

knowledge

South Korea throws huge K

Drastic changes should bring profitability, startup health insurers say

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Friends ask where James Watson's attitudes about race came from

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

explore

knowledge

entertainment

focus